Juul Agrees to Pay $438.5 Million in Settlement with 33 States

Sep.07.2022
Juul Agrees to Pay $438.5 Million in Settlement with 33 States
Juul settles with 33 states for $438.5 million and agrees to stop marketing to youth. Funds will go towards anti-vaping efforts.

E-cigarette company Juul has reached a settlement with 33 states, including Connecticut and Puerto Rico, agreeing to halt certain commercial practices, such as marketing to minors, and pay $438.5 million. The states have stated that the compensation will be used to implement bans on e-cigarettes and reduce nicotine activity.


Connecticut Attorney General William Tong stated in a press release that Juul's advertising campaigns have created a new generation of nicotine addicts.


They ruthlessly sell e-cigarette products to minors, manipulate their chemical composition to cater to non-smokers, use inappropriate age verification procedures, and mislead consumers about the nicotine content and addictive potential of their products. The consequences of this improper behavior on public health are still unclear.


The settlement marks the end of a two-year multi-state investigation. Juul has also agreed to refrain from any sponsorship or naming agreements, cease marketing to all youths, and avoid depicting individuals under the age of 35 in their advertisements.


After an appeal in court in June and reaching a temporary agreement with the U.S. Food and Drug Administration (FDA), Juul has continued to sell its products in the U.S. However, due to FDA regulation and legal battles, the company's market share in the vaping industry has significantly dropped. Back in May 2019, Juul held a dominant 75% market share, but according to VaporVoice, as of June 22, it had dropped to around 34.4%, with competitor Vuse narrowly surpassing Juul in the U.S. Meanwhile, the FDA is pushing for Juul to remove all of its products from U.S. shelves, continuing a thorough safety review of the products.


A spate of illnesses associated with the underground electronic cigarette market across the United States has further damaged Juul's public relations efforts.


In 2019, Juul Labs abandoned a campaign worth $11.6 million aimed at reversing San Francisco's ban on e-cigarette sales. In June 2020, the company announced that it was relocating its headquarters from San Francisco to Washington D.C. and expressed a desire to distance itself from the Silicon Valley startup culture and be closer to politicians and regulators.


According to a report by the Associated Press, Juul is still facing nine independent lawsuits from other states. These include a lawsuit filed by California and Los Angeles in November 2019, which focuses on the company's youth-targeted advertising and alleged failure to warn young consumers about the health risks of vaping. In June, a federal judge in San Francisco allowed a lawsuit against Juul Labs and parent company Altria Group Inc. to proceed on various issues related to misleading marketing.


The Associated Press reports that the company is still facing hundreds of individual consumer lawsuits.


A spokesperson for Juul stated in a press release to the Associated Press, "As we continue to fulfill our mission, we remain focused on our future of transitioning adult smokers from the leading cause of preventable death, combustible cigarettes, while combating underage use.


Statement


This article is sourced from compiled third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of its content. The translation of this article is solely intended for communication and research within the industry.


Due to limitations in our translation abilities, the translated article may not accurately reflect the original text. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on any statements or positions related to domestic, Hong Kong, Macao, Taiwan, and foreign affairs.


The compiled information belongs to the original media and authors in terms of copyright. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
2Firsts First Look|China to End VAT Export Rebates on Vape Devices and Nicotine in April 2027, Following Earlier Removal for HTP Devices and Nicotine Vapes
China's Ministry of Finance and State Taxation Administration announced on October 12, 2026, that value-added tax (VAT) export rebates for vape devices, nicotine and its salts, and certain non-combustible inhalation products will be eliminated from April 1, 2027. The measure adds four tobacco- and nicotine-related customs codes, including 8543400010, which covers vape devices and qualifying empty pods. China previously eliminated rebates for nicotine-containing vaping products and devices under code 8543400090 in April 2026. According to industry classification information held by 2Firsts, the latter currently corresponds to heated tobacco devices. Export excise tax refund and exemption arrangements will remain unchanged.
Special Report
Oct.12
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
Product | SMOORE's VAPORESSO Introduces VAST Refillable Vape With Three Resistances in One Pod
SMOORE-owned vaping brand VAPORESSO introduced the VAST refillable open-system vape in October 2026, featuring Tri-Core Mesh technology that integrates three resistance configurations—0.8Ω, 0.6Ω and 0.4Ω—within a single pod. The device supports different operating modes and e-liquid types. The standard version features a 10mL pod, while a TPD-labelled configuration combines a 2mL pod with an 8mL refill container. The device has a 1,600mAh battery and a maximum output of 30W. VAPORESSO claims up to six pod refills and a tested coil lifespan of up to 150,000 puffs. The UK's MHRA published a related device notification on October 12. The official MSRP is $25.90, compared with a $35.90 listing on VAPORESSO's direct store.
product
Oct.30
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08